SELLAS Life SciencesSLS
About: SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Employees: 15
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
8,320% more call options, than puts
Call options by funds: $18M | Put options by funds: $214K
567% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 6
259% more capital invested
Capital invested by funds: $15.4M [Q1] → $55.4M (+$39.9M) [Q2]
150% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 8
75% more funds holding
Funds holding: 44 [Q1] → 77 (+33) [Q2]
9.6% more ownership
Funds ownership: 15.73% [Q1] → 25.33% (+9.6%) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Maxim Group Jason McCarthy | 266%upside $7 | Buy Maintained | 16 Jul 2025 |
Financial journalist opinion
Based on 3 articles about SLS published over the past 30 days









